Local Project Coordination
Research Associate, Newcastle University Translational and Clinical Research Institute
Dr. Richard Gallon, PhD
Endogenous mechanisms of mutation and the evolutionary theory of carcinogenesis have been my research interests since my undergraduate studies. During my PhD with the Cancer Prevention Research Group, I developed a microsatellite instability assay suitable for high throughput cancer testing, and am supporting its deployment into clinical service both locally and nationally to improve Lynch syndrome screening. I have been working with The Department of Applied Tumour Biology, Heidelberg University Hospital, for several years to show that colorectal tumorigenesis in Lynch syndrome is heterogeneous, and I collaborate with the Medical University of Innsbruck (Austria) developing diagnostic tools to detect Constitutional Mismatch Repair Deficiency, a paediatric cancer predisposition that can occur in Lynch syndrome families. I am currently focused on continued assay development, as well as researching how aspirin intake and the host immune system influence tumour risk and evolution in Lynch syndrome.
Langton DJ, Bourke SC, Lie BA, Reiff G, Natu S, Darlay R, Burn J, Echevarria C. The influence of HLA genotype on the severity of COVID-19 infection. HLA. 2021 Jul;98(1):14-22. doi: 10.1111/tan.14284. Epub 2021 May 4.
Gallon R, Kibbi N, Cook S, Santibanez-Koref M, Jackson MS, Burn J, Rajan N. Sebaceous tumours: a prototypical class of skin tumour for universal germline genetic testing. Br J Dermatol. 2021 May 29.
Gallon R, Gawthorpe P, Phelps RL, Hayes C, Borthwick GM, Santibanez-Koref M, Jackson MS, Burn J. How Should We Test for Lynch Syndrome? A Review of Current Guidelines and Future Strategies. Cancers (Basel). 2021 Jan 22;13(3):406.
Burn J, Sheth H, Elliott F, Reed L, Macrae F, Mecklin JP, Möslein G, McRonald FE, Bertario L, Evans DG, Gerdes AM, Ho JWC, Lindblom A, Morrison PJ, Rashbass J, Ramesar R, Seppälä T, Thomas HJW, Pylvänäinen K, Borthwick GM, Mathers JC, Bishop DT; CAPP2 Investigators. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet. 2020 Jun 13;395(10240):1855-1863.
Gallon R, Sheth H, Hayes C, Redford L, Alhilal G, O’Brien O, Spiewak H, Waltham A, McAnulty C, Izuogu OG, Arends MJ, Oniscu A, Alonso AM, Laguna SM, Borthwick GM, Santibanez-Koref M, Jackson MS, Burn J. Sequencing-based microsatellite instability testing using as few as six markers for high-throughput clinical diagnostics. Hum Mutat. 2020 Jan;41(1):332-341.
Gallon R, Mühlegger B, Wenzel SS, Sheth H, Hayes C, Aretz S, Dahan K, Foulkes W, Kratz CP, Ripperger T, Azizi AA, Baris Feldman H, Chong AL, Demirsoy U, Florkin B, Imschweiler T, Januszkiewicz-Lewandowska D, Lobitz S, Nathrath M, Pander HJ, Perez-Alonso V, Perne C, Ragab I, Rosenbaum T, Rueda D, Seidel MG, Suerink M, Taeubner J, Zimmermann SY, Zschocke J, Borthwick GM, Burn J, Jackson MS, Santibanez-Koref M, Wimmer K. A sensitive and scalable microsatellite instability assay to diagnose constitutional mismatch repair deficiency by sequencing of peripheral blood leukocytes. Hum Mutat. 2019 May;40(5):649-655.
Burn J, Sheth H. The role of aspirin in preventing colorectal cancer. Br Med Bull. 2016 Sep;119(1):17-24.
Burn J, Watson M. The Human Variome Project. Hum Mutat. 2016 Jun;37(6):505-7.
Burn J, Mathers JC, Bishop DT. Chemoprevention in Lynch syndrome. Fam Cancer. 2013 Dec;12(4):707-18.
Burn J, Mathers J, Bishop DT. Lynch syndrome: history, causes, diagnosis, treatment and prevention (CAPP2 trial). Dig Dis. 2012;30 Suppl 2:39-47.
Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard ML, Dunlop MG, Ho JW, Hodgson SV, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar R, Side L, Scott RJ, Thomas HJ, Vasen HF, Barker G, Crawford G, Elliott F, Movahedi M, Pylvanainen K, Wijnen JT, Fodde R, Lynch HT, Mathers JC, Bishop DT; CAPP2 Investigators. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011 Dec 17;378(9809):2081-7.